USE OF SOLUBLE NRP1 POLYPEPTIDES FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
The present application relates to the treatment of coronavirus infection such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related diseases. The treatment is achieved by the administration of soluble neuropilin-1 (NRP1) polypeptides that compete with endogenous NRP1 and ACE2 for binding to the spike (S) glycoprotein from the coronavirus envelope..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 30. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SAPIEHA PRZEMYSLAW [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-30, Last update posted on www.tib.eu: 2022-09-12, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
WO2021258218 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013574736 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013574736 | ||
| 003 | DE-627 | ||
| 005 | 20230504072023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013574736 | ||
| 035 | |a (EPA)WO2021258218 | ||
| 035 | |a (EPA)79282606 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SAPIEHA PRZEMYSLAW |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a USE OF SOLUBLE NRP1 POLYPEPTIDES FOR THE TREATMENT OF CORONAVIRUS INFECTIONS |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-30, Last update posted on www.tib.eu: 2022-09-12, Last updated: 2023-02-09 | ||
| 520 | |a The present application relates to the treatment of coronavirus infection such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related diseases. The treatment is achieved by the administration of soluble neuropilin-1 (NRP1) polypeptides that compete with endogenous NRP1 and ACE2 for binding to the spike (S) glycoprotein from the coronavirus envelope. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BEAULIEU NORMAND |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/79282606/publication/WO2021258218A1?q=WO2021258218 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2021 |b 30 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||